Clinical bottom line
Refractory sicca symptoms in primary Sjögren’s syndrome (pSS) remain a significant clinical challenge, with limited effective treatment options beyond conventional artificial tears and saliva substitutes. Emerging therapies, including novel topical agents and biologics, show promise but lack robust, large-scale evidence for routine use. Current data suggest that targeted therapies may benefit select patients with severe ocular and oral dryness unresponsive to standard care, but clinical responses are variable and require further validation. Clinicians should maintain a comprehensive, multidisciplinary approach incorporating symptomatic management, patient coping strategies, and careful monitoring for systemic involvement.
What the evidence shows
Sicca symptoms, primarily dry eyes and dry mouth, are hallmark features of pSS and significantly impair quality of life (Karaarslan et al., 2022). While standard treatments such as artificial tears and saliva substitutes remain first-line, a subset of patients experience refractory symptoms that do not adequately respond to these measures (Ostuni et al., 2011). Ostuni and colleagues (2011) evaluated Carbopol 974P (Siccafluid), a novel topical gel, in patients with moderate to severe keratoconjunctivitis sicca secondary to pSS who were refractory to standard artificial tears. Their study demonstrated symptomatic improvement and better ocular surface protection, suggesting a potential role for this agent in difficult-to-treat cases.
Beyond topical therapies, biologic agents targeting B cells and inflammatory pathways have been explored. Brito-Zerón et al. (2011) reviewed various biologics in pSS, highlighting their potential to modulate systemic disease activity and possibly improve sicca symptoms. However, clinical trials remain limited, and evidence for efficacy specifically on refractory sicca manifestations is preliminary.
Patient coping mechanisms and quality of life considerations are critical, as highlighted by a qualitative study exploring ocular symptom management in pSS (Rheumatology, 2015). This underscores the need for individualized care plans that address both physical symptoms and psychosocial impact.
Uncommon presentations, such as pSS manifesting with systemic features prior to sicca symptoms, have been reported (Erdem et al., 2017; Yarrabathina et al., 2024). These cases emphasize the heterogeneity of pSS and the importance of vigilance for systemic involvement that may influence therapeutic decisions.
Caveats and uncertainty
The evidence base for novel therapies in refractory sicca symptoms is limited by small sample sizes, heterogeneous patient populations, and a lack of randomized controlled trials specifically targeting this subgroup. The study by Ostuni et al. (2011) remains one of the few addressing topical agents beyond standard care, but its findings require replication and extension in larger cohorts.
Biologic therapies, while promising, have not yet demonstrated consistent benefit for sicca symptoms in controlled settings, and their safety profiles in pSS warrant careful consideration. Moreover, the variability in symptom severity and patient-reported outcomes complicates assessment of therapeutic efficacy.
The natural history of pSS, including cases with delayed or atypical sicca presentation, adds complexity to treatment timing and selection (Erdem et al., 2017; Yarrabathina et al., 2024). Clinicians must balance aggressive intervention with potential adverse effects, especially in elderly or comorbid populations (Karaarslan et al., 2022).
How this may change practice
Clinicians managing pSS patients with refractory sicca symptoms should consider adjunctive therapies such as Carbopol 974P gel in those unresponsive to conventional artificial tears, recognizing the need for individualized assessment and monitoring (Ostuni et al., 2011). Incorporating patient education on coping strategies and psychosocial support is essential to optimize quality of life (Rheumatology, 2015).
While biologic therapies remain investigational for sicca symptom relief, referral to specialized centers or clinical trials may be appropriate for patients with severe systemic disease or refractory symptoms (Brito-Zerón et al., 2011; Fisher et al., 2021). Awareness of atypical presentations and systemic manifestations should prompt comprehensive evaluation to guide therapy (Erdem et al., 2017; Yarrabathina et al., 2024).
Overall, management should remain multidisciplinary, integrating rheumatology, ophthalmology, dentistry, and allied health services to address the multifaceted challenges of refractory sicca in pSS.